Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase (Q42169332)

17 October 2017

Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase (English)

1 reference

17 October 2017

3

1 reference

17 October 2017

4

1 reference

17 October 2017

5

Vern L Schramm

1 reference

17 October 2017

2

Peter C Tyler

1 reference

17 October 2017

1

Andrzej Lewandowicz

1 reference

PubMed ID

12842889

17 October 2017

language of work or name

English

0 references

publication date

3 July 2003

1 reference

Journal of Biological Chemistry

17 October 2017

1 reference

17 October 2017

278

1 reference

17 October 2017

31465-31468

1 reference

17 October 2017

34

1 reference

Deoxyguanosine toxicity on lymphoid cells as a cause for immunosuppression in purine nucleoside phosphorylase deficiency

17 October 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Deoxyguanosine Triphosphate as a Possible Toxic Metabolite in the Immunodeficiency Associated with Purine Nucleoside Phosphorylase Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Expression of a cDNA sequence encoding human purine nucleoside phosphorylase in rodent and human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Imino-sugar-based nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Over-the-barrier transition state analogues and crystal structure with Mycobacterium tuberculosis purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Ionic states of substrates and transition state analogues at the catalytic sites of N-ribosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Inhibition of uracil DNA glycosylase by an oxacarbenium ion mimic

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Synthesis of Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase and N-Riboside Hydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

21 January 2018

Identifiers

DOI

10.1074/JBC.C300259200

1 reference

17 October 2017

1 reference

PubMed ID

12842889